Results 151 to 160 of about 3,879,639 (303)

Calculate the concentration of a substance

, 2007
A pdf document on calculating the concentration of a substance in a mixture.

core  

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Molecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober, Leire Moreno‐Cugnon, Laura Martínez‐Pérez, Amaia Ercilla, Amaia Zabala‐Letona, Adrián Vicente‐Barrueco, Maider Fagoaga‐Eugui, Saioa Garcia‐Longarte, Blanca Calle‐Ciborro, Encarnación Pérez‐Andrés, Onintza Carlevaris, Sara Pozo, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Violaine Sée, Edurne Berra   +16 more
wiley   +1 more source

Peer review of the pesticide risk assessment of the active substance choline hydrogen phosphonate. [PDF]

EFSA J
European Food Safety Authority (EFSA), Álvarez F, Arena M, Auteri D, Leite SB, Binaglia M, Castoldi AF, Chiusolo A, Colagiorgi A, Colas M, Crivellente F, De Lentdecker C, De Magistris I, Egsmose M, Fait G, Ferilli F, Santonja GG, Gouliarmou V, Ippolito A, Istace F, Kardassi D, Kienzler A, Lanzoni A, Lava R, Leuschner R, Linguadoca A, Romano ML, Louisse J, Lythgo C, Magrans O, Mangas I, Mazzega S, Mioč A, Miron I, Molnar T, Padovani L, Padricello V, Panzarea M, Parra Morte JM, Rizzuto S, Santos M, Serafimova R, Sharp R, Szentes C, Theobald A, Tiramani M, Vianello G, Villamar-Bouza L.   +47 more
europepmc   +1 more source

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

Molecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder, Klaas de Lint, Hồ Mỹ Phúc Võ, Mariana M. Góis, Rosalie A. Kampen, Marta San Martin Alonso, Ilse Nootenboom, Veronica Garzero, Tiemen J. Wendel, Rob M. F. Wolthuis, Sylvie M. Noordermeer   +10 more
wiley   +1 more source

Peer review of the pesticide risk assessment of the active substance 8-methyldecan-2-yl propanoate. [PDF]

EFSA J
European Food Safety Authority (EFSA), Álvarez F, Arena M, Auteri D, Leite SB, Binaglia M, Castoldi AF, Chiusolo A, Colagiorgi A, Colas M, Crivellente F, De Lentdecker C, De Magistris I, Egsmose M, Fait G, Ferilli F, Santonja GG, Gouliarmou V, Ippolito A, Istace F, Kardassi D, Kienzler A, Lanzoni A, Lava R, Leuschner R, Linguadoca A, Romano ML, Louisse J, Lythgo C, Magrans O, Mangas I, Mazzega S, Mioč A, Miron I, Molnar T, Padovani L, Padricello V, Panzarea M, Parra Morte JM, Rizzuto S, Santos M, Serafimova R, Sharp R, Szentes C, Theobald A, Tiramani M, Vianello G, Villamar-Bouza L.   +47 more
europepmc   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Peer review of the pesticide risk assessment of the active substance <i>Trichoderma asperellum</i>T34. [PDF]

EFSA J
European Food Safety Authority (EFSA), Álvarez F, Arena M, Auteri D, Leite SB, Binaglia M, Castoldi AF, Chiusolo A, Colagiorgi A, Colas M, Crivellente F, De Lentdecker C, De Magistris I, Egsmose M, Fait G, Ferilli F, Santonja GG, Gouliarmou V, Ippolito A, Istace F, Kardassi D, Kienzler A, Lanzoni A, Lava R, Leuschner R, Linguadoca A, Romano ML, Louisse J, Lythgo C, Magrans O, Mangas I, Mazzega S, Mioč A, Miron I, Molnar T, Padovani L, Padricello V, Panzarea M, Morte JMP, Rizzuto S, Santos M, Marchese AS, Serafimova R, Sharp R, Szentes C, Theobald A, Tiramani M, Vianello G, Villamar-Bouza L.   +48 more
europepmc   +1 more source

Prediction of activity spectra for substances

Journal of Pharmacology and Pharmacotherapeutics, 2011
openaire   +3 more sources

SUBSTANCE ABUSE TREATMENT: WHAT DO WE KNOW? AN ECONOMIST’S PERSPECTIVE [PDF]

The substance abuse treatment literature has basically dealt with four important questions: 1) Is treatment effective? 2) Are all programs equally effective? 3) why do programs differ in their effectiveness?
Matilde P. Machado
core  

Oncogenic DMTF1β promotes cancer cell motility by regulating autophagy through ULK1 stabilization

Molecular Oncology, EarlyView.
In the current study, we demonstrate that the oncogene DMTF1β regulates ULK1 stability by reducing its proteasomal degradation in cancer cells. This stabilization enables ULK1 to induce autophagy, which in turn facilitates cancer cell migration. Consequently, reduced DMTF1β levels lead to decreased autophagy and impaired cancer cell migration.
Jun Xu, Nicolas J. Niklaus, Anna M. Schläfli, Igor Tokarchuk, Magali Humbert, Federico La Manna, Bich Vu, David Maul, Ramin Radpour, Marianna Kruithof‐de Julio, Inti Zlobec, Jörn Dengjel, Bruce E. Torbett, Mario P. Tschan   +13 more
wiley   +1 more source